Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?

Area of Science:

• Hematology
• Oncology
• Diagnostic Imaging

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Accurate staging is crucial for risk assessment and treatment planning in DLBCL.
• Bone marrow biopsy (BMB) is a component of the standard staging work-up.

Purpose of the Study:

• To evaluate the added value of bone marrow biopsy (BMB) in the staging of newly diagnosed diffuse large B-cell lymphoma (DLBCL).
• To assess the impact of BMB on risk stratification and treatment decisions.
• To determine if BMB provides additional prognostic information beyond standard staging methods.

Main Methods:

• Retrospective analysis of 113 newly diagnosed DLBCL patients.
• Standard pretreatment evaluation including imaging and lactate dehydrogenase.
• Assessment of National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) with and without BMB results.
• Evaluation of changes in risk stratification and treatment planning based on BMB findings.

Main Results:

• Bone marrow biopsy (BMB) was positive in 15.9% of patients.
• BMB results led to changes in NCCN-IPI risk stratification for 8.0% of patients.
• No patient experienced a change in their planned treatment due to BMB findings.

Conclusions:

• Bone marrow biopsy (BMB) upstaged risk stratification in a small subset of DLBCL patients.
• BMB findings did not influence therapeutic strategies in this cohort.
• The routine use of BMB in the staging of newly diagnosed DLBCL may be reconsidered in the current era.